irinotecan/breast neoplasms

FIELD OF THE INVENTION This invention relates to (among other things) the field of cancer chemotherapy. More specifically, the invention involves the treatment of an individual suffering from a cancer such as breast cancer by administering to the individual a long-acting topoisomerase I inhibitor,

TECHNICAL FIELD The present invention relates to a method of treating cancer by co-administration of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-- 1H-naphtho[2,3-d]imidazol-3-ium bromide and one or more other anticancer agents. The present invention also relates to the

TECHNICAL FIELD The present invention relates to a method of treating cancer by co-administration of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-- 1H-naphtho[2,3-d]imidazol-3-ium bromide and one or more other anticancer agents. The present invention also relates to the

BACKGROUND Numerous high-grade malignancies and precancerous conditions exist that are difficult to treat, prevent and eradicate. Many of such conditions are affiliated with breast cancer, prostate cancer, skin cancer, oral cancer, and precancerous conditions thereof. Furthermore, current treatment

SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Mar. 8, 2016, is named IMM356US1_SL.txt and is 26,230 bytes in size. FIELD OF THE